JP7343123B2 - 性機能低下の治療及び性的な生活の質の向上 - Google Patents

性機能低下の治療及び性的な生活の質の向上 Download PDF

Info

Publication number
JP7343123B2
JP7343123B2 JP2020519007A JP2020519007A JP7343123B2 JP 7343123 B2 JP7343123 B2 JP 7343123B2 JP 2020519007 A JP2020519007 A JP 2020519007A JP 2020519007 A JP2020519007 A JP 2020519007A JP 7343123 B2 JP7343123 B2 JP 7343123B2
Authority
JP
Japan
Prior art keywords
stem cells
mesenchymal stem
composition
sexual
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524179A (ja
JP2020524179A5 (enExample
Inventor
ダーシー エル． ディフェデ，
ジョシュア エム． ヘア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Publication of JP2020524179A publication Critical patent/JP2020524179A/ja
Publication of JP2020524179A5 publication Critical patent/JP2020524179A5/ja
Application granted granted Critical
Publication of JP7343123B2 publication Critical patent/JP7343123B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020519007A 2017-06-19 2018-06-15 性機能低下の治療及び性的な生活の質の向上 Active JP7343123B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762521765P 2017-06-19 2017-06-19
US62/521,765 2017-06-19
PCT/US2018/037725 WO2018236680A1 (en) 2017-06-19 2018-06-15 TREATMENT OF SEXUAL DYSFUNCTION AND IMPROVEMENT OF THE QUALITY OF SEXUAL LIFE

Publications (3)

Publication Number Publication Date
JP2020524179A JP2020524179A (ja) 2020-08-13
JP2020524179A5 JP2020524179A5 (enExample) 2021-07-29
JP7343123B2 true JP7343123B2 (ja) 2023-09-12

Family

ID=62952383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519007A Active JP7343123B2 (ja) 2017-06-19 2018-06-15 性機能低下の治療及び性的な生活の質の向上

Country Status (12)

Country Link
US (1) US12496316B2 (enExample)
EP (1) EP3641793A1 (enExample)
JP (1) JP7343123B2 (enExample)
KR (1) KR20200017516A (enExample)
CN (1) CN111107858A (enExample)
AU (1) AU2018288653A1 (enExample)
CA (1) CA3067354A1 (enExample)
IL (1) IL271395A (enExample)
SG (1) SG11201912209UA (enExample)
TW (1) TW201919664A (enExample)
WO (1) WO2018236680A1 (enExample)
ZA (1) ZA201908451B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021340971A1 (en) 2020-09-08 2023-03-30 Longeveron, Inc. Treatment of Alzheimer's disease with allogeneic mesenchymal stem cells
EP4376950A1 (en) 2021-07-26 2024-06-05 Longeveron Inc. Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome
CA3226181A1 (en) 2021-09-10 2023-03-16 Longeveron Inc. Treatment of aging frailty comprising administering bone marriw derived mesenchymal stem cells
KR102762783B1 (ko) * 2022-01-21 2025-02-05 고현서 심리 프로파일에 따른 행동 습관 제공 방법, 서버, 저장 매체 및 디바이스
WO2025137077A1 (en) 2023-12-19 2025-06-26 Longeveron, Inc. Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells
WO2025199451A2 (en) 2024-03-21 2025-09-25 Longeveron Inc. Mmp-14 potency assay for mesenchymal stem cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
WO2007149548A2 (en) * 2006-06-22 2007-12-27 Medistem Laboratories, Inc. Treatment of erectile dysfunction by stem cell therapy
WO2010021996A1 (en) * 2008-08-18 2010-02-25 Junta De Beneficiencia De Guayaquil Treatment of injuries to the central nervous system
EP2486930B1 (en) 2009-10-06 2016-03-23 National University Corporation Nagoya University Cell preparation containing adipose tissue derived mesenchymal stem cells for use in the treatment of a condition of no urge to urinate
WO2013173694A2 (en) * 2012-05-18 2013-11-21 The Cooper Health System A method of restoring endothelial/smooth muscle architecture and cell signaling pathways to sexual organs
EA202190962A2 (ru) 2014-05-30 2022-02-28 Оникс Терапьютикс, Инк. Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом
CN105055450A (zh) 2015-02-13 2015-11-18 中国福利会国际和平妇幼保健院 人宫内膜干细胞在制备治疗卵巢早衰的药物中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Gerontology: MEDICAL SCIENCES，2003年，Vol. 58A, No. 5，pp. , 409-416
Journal of Women's Health & Gender-Based Medicine，2004年，Vol. 9, No. supplement 1，https://doi.org/10.1089/152460900318812
Journals of Gerontology Series A: Medical Sciences，2017年04月21日，Vol. 72, No. 11，pp. 1505-0512

Also Published As

Publication number Publication date
US12496316B2 (en) 2025-12-16
CN111107858A (zh) 2020-05-05
SG11201912209UA (en) 2020-01-30
AU2018288653A1 (en) 2020-01-16
JP2020524179A (ja) 2020-08-13
TW201919664A (zh) 2019-06-01
WO2018236680A1 (en) 2018-12-27
ZA201908451B (en) 2021-05-26
EP3641793A1 (en) 2020-04-29
US20200129558A1 (en) 2020-04-30
CA3067354A1 (en) 2018-12-27
IL271395A (en) 2020-01-30
KR20200017516A (ko) 2020-02-18

Similar Documents

Publication Publication Date Title
JP7343123B2 (ja) 性機能低下の治療及び性的な生活の質の向上
DK2744892T3 (en) THERAPEUTICS USING FAT CELLS AND CELL SECRETIONS
JP7680493B2 (ja) 免疫疾患の治療
EP3046417B1 (en) Methods of using adipose tissue-derived cells in the treatment of raynaud's phenomenon associated with scleroderma
US20240009233A1 (en) Macrophage Cell Therapy to Treat Orthopedic Injury
Yeghiazarians et al. IL-15: a novel prosurvival signaling pathway in cardiomyocytes
US20250281542A1 (en) Mesenchymal stem cells for oral inflammation treatment
KR102330083B1 (ko) 포유류 탯줄 유래 줄기세포 배양액을 유효성분으로 포함하는 근위축증의 예방 또는 치료용 약제학적 조성물
JP2023002772A (ja) 脂肪細胞および細胞分泌物を使用する治療
KR101680834B1 (ko) 알파 리포산을 포함하는 갑상선 안병증의 예방 또는 치료용 약제학적 조성물
Protogerou et al. Stem cell therapy for erectile dysfunction: preliminary results from a single-center pilot study in Greece
US20160243198A1 (en) Pharmaceutical Composition for Preventing or Treating Osteoporosis Which Comprises Neuropeptide Y as Active Ingredient
HK40109512A (zh) 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
JP2024517954A (ja) 肝疾患を治療するための方法および組成物
WO2014047688A1 (en) Therapeutics using multiple injections of cells
HK1226601B (en) Methods of using adipose tissue-derived cells in the treatment of raynaud’s phenomenon associated with scleroderma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230823

R150 Certificate of patent or registration of utility model

Ref document number: 7343123

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150